Isla P. Garraway

Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients

This study reports a 5.4% rate of pathogenic germline variants in a racially diverse cohort of prostate cancer patients, with significant associations between PGV rates and age at diagnosis and self-identified race.

Germline polygenic score for prostate cancer aggressiveness

This paper develops a germline polygenic score (PRSagg) to predict prostate cancer aggressiveness and validates it across multiple datasets.

Association of HOXB13 G84E with prostate cancer among 592,158 men

This paper shows the HOXB13 p.G84E variant increases prostate cancer risk by threefold in men, but does not lead to more aggressive cancer.

Polyploid cancer cells reveal signatures of chemotherapy resistance

The paper identifies polyploid cancer cells as markers of chemotherapy resistance and recurrence in prostate cancer, linking them to poorer survival outcomes.

From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study

The paper develops a polygenic risk model for prostate cancer using VA data and validates it in external cohorts, showing its clinical utility in risk stratification.

Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation Sequencing

This study analyzes genomic alterations in metastatic prostate cancer patients across racial groups, finding race-associated differences in mutation frequencies and survival outcomes.